Skip to main content
Search
Main content
Alzheimer's & dementia : the journal of the Alzheimer's Association
Published

Development of language composites for enhanced sensitivity to multiple plasma biomarkers

Authors

Deling He, Rebecca E Langhough, Carol Van Hulle, Kristin Basche, Erin Jonaitis, Rachael Wilson, Bruce Hermann, Henrik Zetterberg, Sterling Johnson, Kimberly D Mueller

Abstract

Alzheimers Dement. 2025 Dec;21(12):e70975. doi: 10.1002/alz.70975.

ABSTRACT

BACKGROUND: While language deficits are among the earliest detectable signs of Alzheimer`s disease (AD), no existing composites integrate connected speech - essential for capturing real-world communication - limiting precise detection and personalized interventions.

METHODS: We analyzed cohort data from 824 non-demented adults and constructed three language composites: a theoretical composite based on expert knowledge, a connected speech-specific composite derived from the theoretical composite, and an empirical language composite optimized for predicting cognitive progression. We compared their longitudinal sensitivity to plasma tau phosphorylated at threonine 217 (p-tau217), neurofilament light (NfL), and glial fibrillary acidic protein (GFAP).

RESULTS: The empirical language composite showed superior and consistent sensitivity (faster decline rate) with all three biomarkers. Proper name recall declined uniquely with increased p-tau217, while animal fluency declined selectively with higher NfL and GFAP.

DISCUSSION: An empirical language composite captures holistic cognitive-communicative decline, while individual measures may imply a biomarker-specific language profile. Our findings support the clinical utility of plasma biomarkers and language-specific composites as sensitive early indicators of disease progression.

HIGHLIGHTS: Empirical language composite had optimal sensitivity to plasma p-tau217, NfL, GFAP. It comprises words/minute, filled pauses, proper name recall, and animal fluency. It offers potential for language-dominant ADRD precise detection and monitoring.

PMID:41366787 | DOI:10.1002/alz.70975

UK DRI Authors

Profile picture of Henrik Zetterberg

Prof Henrik Zetterberg

Group Leader

Pioneering the development of fluid biomarkers for dementia

Prof Henrik Zetterberg